AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3291787
Drug: Single component
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single component measles vaccine
Trial: 31313720
Drug: Nasal CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal CPAP (SuperNO2VA) at 10 cmH2O, oxygen flow rate of 15 l/min
Trial: 31313720
Drug: Oxygen via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen via nasal cannula at 5 l/min
Trial: 28198722
Drug: Stand-alone Physician
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stand-alone Physician Orders for Life-Sustaining Treatment (POLST) and living will (LW) documents
Trial: 23556549
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg IV pre-treatment
Trial: 9337947
Drug: Brief cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive therapy (BCT) plus 'treatment as usual'
Trial: 9337947
Drug: Brief cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive therapy (BCT)
Trial: 8210821
Drug: Transfer non-adherers
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer non-adherers to alternative treatment group at randomization
Trial: 8210821
Drug: Censor non-adherers
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Censor non-adherers at time of treatment change
Trial: 8210821
Drug: Transfer non-adherers
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer non-adherers to alternative treatment group at time of treatment change
Trial: 3320901
Drug: I.V. cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. cefuroxime (1.5 g)
Trial: 27008297
Drug: Intrathecal 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 0.5% bupivacaine 3 mL with 2.5 µg dexmedetomidine
Trial: 27008297
Drug: Intrathecal 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 0.5% bupivacaine 3 mL with 5 µg dexmedetomidine
Trial: 27008297
Drug: Intrathecal 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 0.5% bupivacaine 3 mL with 10 µg dexmedetomidine
Trial: 20107146
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg for infants, 20 mg for older children) for 4 months
Trial: 14712886
Drug: Telmisartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40 mg uptitrated to 80 mg after four weeks, if needed)
Trial: 8910097
Drug: 3‐carbon compounds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐carbon compounds pyruvate and dihydroxyacetone (PD)
Trial: 28013097
Drug: Prequit Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prequit Nicotine Patch
Trial: 28013098
Drug: Preparation Counseling
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation Counseling
Trial: 28013098
Drug: 16 Weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16 Weeks of Combination Nicotine Replacement Therapy (NRT)
Trial: 28013098
Drug: 8 Weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 Weeks of Combination Nicotine Replacement Therapy (NRT)
Trial: 27290960
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dexketoprofen trometamol
Trial: 24398115
Drug: Relaxation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation and imagination therapies
Trial: 20353109
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment in active stage group
Trial: 20353109
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment in resting stage group
Trial: 20353109
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment in recovery stage group
Trial: 2232833
Drug: Standard hypothermic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hypothermic cardioplegic solution
Trial: 2232833
Drug: Cardioplegic solution
RxNorm normalized name: cardioplegic solution no.2
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cardioplegic solution supplemented with deferoxamine 1000 mg/L
Trial: 758132
Drug: Propylthiouracil (PTU)
RxNorm normalized name: Propylthiouracil
DrugBank: Propylthiouracil (DB00550)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propylthiouracil (PTU) 300 mg daily
Trial: 30190299
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle
Trial: 30522967
Drug: Lomustine 110
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lomustine 110 mg/m2 once every 6 weeks
Trial: 25193976
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy for psychosis (CBTp)
Trial: 25193976
Drug: Multi-modal Cognitive
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-modal Cognitive treatment (combination of CBTp and CAT)
Trial: 21781528
Drug: Taxol and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxol and cisplatin combined chemotherapy (TP)
Trial: 20205024
Drug: Genetic/biological attributions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic/biological attributions of obesity
Trial: 15266195
Drug: LISA-T prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LISA-T prevention program (cognitive-behavioral therapy concepts, 10 meetings of 1.5 hours)
Trial: 9150331
Drug: Home intravenous
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home intravenous (i.v.) antibiotic therapy
Trial: 8429112
Drug: Zofenopril calcium
RxNorm normalized name: zofenopril calcium
DrugBank: Zofenopril (DB13166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofenopril calcium (7.5 mg, 15 mg, 30 mg)
Trial: 3113280
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG) 10 mg four times daily
Trial: 19626326
Drug: CT colonography
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT colonography with limited bowel preparation (180 ml diatrizoate meglumine, 80 ml barium, 30 mg bisacodyl)
Trial: 19626326
Drug: Colonoscopy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colonoscopy with full preparation (4 l of polyethylene glycol solution)
Trial: 16579802
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (various doses)
Trial: 16579802
Drug: Flax oil
RxNorm normalized name: Flax oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flax oil (2.2 g of alpha-linolenic acid per day)
Trial: 1577155
Drug: i.v. salbutamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. salbutamol treatment (5 micrograms.kg‐1)
Trial: 1577155
Drug: inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: inhaled salbutamol (0.15 mg.kg‐1 x 2)
Trial: 6515508
Drug: Amoxycillin 1500
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 1500 mg/d for 2 weeks and 1000 mg/d for 12 weeks thereafter
Trial: 6515508
Drug: Erythromycin stearate
RxNorm normalized name: Erythromycin Stearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin stearate 1500 mg/d for 2 weeks and 1000 mg/d for 12 weeks thereafter
Trial: 27015283
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg/kg plus naproxen 1,000 mg/day
Trial: 27015283
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus naproxen 1,000 mg/day
Trial: 22584564
Drug: Intensive educational
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive educational intervention (GI) with six weekly visits
Trial: 22584564
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (GC)
Trial: 17999650
Drug: Acid infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acid infusion (HCl, 0.1 mol L(‐1))
Trial: 14589461
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment of neck pain
Trial: 1660823
Drug: Erythromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (10 g in 40 doses over 10 days)
Trial: 1660823
Drug: Amoxycillin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (15 g in 30 doses over 10 days)
Trial: 7138752
Drug: Combined formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined formulation of long-acting propranolol/bendrofluazide (Inderex)
Trial: 7138752
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three preparations (LA propranolol, LA propranolol and bendrofluazide, combined formulation)
Trial: 7138752
Drug: Bendrofluazide in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide in two preparations
Trial: 30132786
Drug: (-)-OSU6162 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (-)-OSU6162 15 mg twice daily for 4 weeks, then 30 mg twice daily for 4 weeks, then 45 mg twice daily for 4 weeks
Trial: 27725493
Drug: Prasugrel 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 20 mg
Trial: 20374400
Drug: Computer-generated dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-generated dosing group (CGD)
Trial: 17666020
Drug: 100 mug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mug vitamin K once daily
Trial: 8002535
Drug: Benzodiazepine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine (1.5 mg lorazepam)
Trial: 2907669
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg almitrine bismethylate
Trial: 28732324
Drug: FEC-Doc (taxane-anthracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC-Doc (taxane-anthracycline based chemotherapy)
Trial: 26745107
Drug: Conventional Cytology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Cytology (CC)
Trial: 23427334
Drug: Polydextrose (PDX)
RxNorm normalized name: Polydextrose
DrugBank: Polydextrose (DB14836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polydextrose (PDX) at a dose of 20 g/d
Trial: 23427334
Drug: Soluble corn
RxNorm normalized name: soluble corn fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble corn fiber (SCF) at a dose of 20 g/d
Trial: 8838821
Drug: Rice-based oral
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice-based oral rehydration solution (50 g/l)
Trial: 2248588
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment following removal of the foreign body
Trial: 6998553
Drug: High-dose methotrexate-citrovorum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate-citrovorum factor rescue plus cyclophosphamide (MECY)
Trial: 26644527
Drug: Symptom monitoring
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom monitoring via tablet computers
Trial: 24324046
Drug: Amlodipine-based treatment
RxNorm normalized name: Amlodipine free base
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine-based treatment (NT-proBNP below median)
Trial: 9850427
Drug: New amitriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New amitriptyline tablet formulation (amitriptylin 25 von ct)
Trial: 9850427
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (28.3 mg amitriptyline hydrochloride)
Trial: 2679853
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose metoclopramide with dexamethasone and lorazepam
Trial: 30311085
Drug: 0.1 mg/mL
RxNorm normalized name: deanol 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/mL TBO
Trial: 30311085
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of TBO and diode laser
Trial: 26438556
Drug: Oral sucrose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sucrose, 0.5 mL of 24% sucrose administered orally via syringe, 2 minutes before heel lancing.
Trial: 23750463
Drug: Interpersonally focused
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonally focused therapy-cognitive behavioral analysis system of psychotherapy (CBASP)
Trial: 7915773
Drug: IVIgG 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIgG 0.8 g/kg once
Trial: 7915773
Drug: IVIgG 1
RxNorm normalized name: IVIgGM
DrugBank: Pentaglobin (DB15865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIgG 1 g/kg on 2 consecutive days
Trial: 7915773
Drug: Intravenous anti-D
RxNorm normalized name: anti-D (rh) immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anti-D 25 micrograms/kg on 2 consecutive days
Trial: 7915773
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone 4 mg/kg per day with tapering and discontinuation by day 21
Trial: 2583258
Drug: 5-drug combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-drug combination MOCCA
Trial: 31307503
Drug: Nifurtimox (NFX)
RxNorm normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifurtimox (NFX) 480 mg/day for 120 days
Trial: 31307503
Drug: Benznidazole (BZN)
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole (BZN) 300 mg/day for 60 days followed by placebo for 60 days
Trial: 31307503
Drug: Benznidazole (BZN)
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole (BZN) 150 mg/day for 120 days
Trial: 31307503
Drug: Nifurtimox (NFX)
RxNorm normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifurtimox (NFX) 240 mg/day for 120 days
Trial: 22905856
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dolutegravir (DTG) 50 mg once daily
Trial: 8515544
Drug: Methylprednisolone (MPS)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MPS) 15 mg.kg‐1 i.v. 60 minutes after CPB
Trial: 8515544
Drug: No Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No Methylprednisolone (MPS) administration
Trial: 2835788
Drug: Topical LTB4
RxNorm normalized name: LTB4
DrugBank: Leukotriene B4 (DB12961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical LTB4 (100-900 ng applied once a week for up to 7 weeks depending on lesion type)
Trial: 28941259
Drug: Aripiprazole (1–15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (1–15 mg/day)
Trial: 24239295
Drug: Oral probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral probiotic capsules for 7 days
Trial: 22266741
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.5% bupivacaine
Trial: 19517661
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.5% bupivacaine with 0.5 mg neostigmine
Trial: 15925049
Drug: Cetrorelix (GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrorelix (GnRH antagonist)
Trial: 15925049
Drug: Busereline (GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busereline (GnRH agonist)
Trial: 24798870
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg JNJ-41443532
Trial: 24798870
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg JNJ-41443532
Trial: 22695756
Drug: Sublingual nicotine
RxNorm normalized name: nicotine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nicotine tablets (SNT)
Trial: 20484175
Drug: β-carotene (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-carotene (20 mg per day)
Trial: 15645186
Drug: Oral tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tramadol 50 mg (drops) followed by tramadol sustained release 100 mg orally, placebo rectally
Trial: 15645186
Drug: Rectal tramadol
RxNorm normalized name: tramadol hydrochloride Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal tramadol 100 mg, placebo orally
Trial: 31742316
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (20 mL)
Trial: 28089528
Drug: Hydrogel spacer
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel spacer infiltration into the rectal wall
Trial: 26071975
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no β-blocker therapy)
Trial: 14980926
Drug: PCEA (ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA (ropivacaine 3.2 mg plus fentanyl 8 microg/dose) with DM 90 mg
Trial: 14980926
Drug: IV-PCA (morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV-PCA (morphine 2 mg/dose) with DM 90 mg
Trial: 14980926
Drug: PCEA (ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA (ropivacaine 3.2 mg plus fentanyl 8 microg/dose) with placebo
Trial: 14980926
Drug: IV-PCA (morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV-PCA (morphine 2 mg/dose) with placebo
Trial: 25039272
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of sildenafil 100mg and vacuum erection device
Trial: 20206891
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous (cIV) furosemide
Trial: 20206891
Drug: Intermittent intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intravenous (iIV) furosemide
Trial: 17635508
Drug: Active lotion
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active lotion containing triethyl citrate and ethyl linoleate
Trial: 2859075
Drug: Nine months'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nine months' chemotherapy with rifampicin plus isoniazid supplemented by ethambutol for eight weeks
Trial: 2859075
Drug: Eighteen months'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eighteen months' chemotherapy with rifampicin plus isoniazid supplemented by ethambutol for eight weeks
Trial: 23658561
Drug: Aerobic dance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic dance combined with drug therapy (Hydrochlorothiazide + amiloride hydrochloride, and Amlodipine)
Trial: 23658561
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (Hydrochlorothiazide + amiloride hydrochloride, and Amlodipine)
Trial: 19842829
Drug: Condom availability
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Condom availability in treatment programs
Trial: 9323505
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 2 liter daily exchange
Trial: 9323505
Drug: 4 daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 daily exchanges
Trial: 8405010
Drug: Ipratropium 80
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium 80 mg q.i.d.
Trial: 31667338
Drug: Letrozole +
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole + Dasatinib (100 mg/day PO)
Trial: 31667338
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg/day PO)
Trial: 30742373
Drug: Imidafenacin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidafenacin 0.1 mg, twice a day for 12 weeks